(Q34623166)

English

Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 August 2017

Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas (English)

1 reference

Europe PubMed Central

3 August 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

author name string

Sheng-Hwu Hsieh

1

1 reference

Europe PubMed Central

3 August 2017

Kuang-Chung Shih

2

1 reference

Europe PubMed Central

3 August 2017

Chien-Wen Chou

3

1 reference

Europe PubMed Central

3 August 2017

Chih-Hsun Chu

4

1 reference

Europe PubMed Central

3 August 2017

publication date

21 October 2010

1 reference

Europe PubMed Central

3 August 2017

Acta Diabetologica

1 reference

Europe PubMed Central

3 August 2017

48

1 reference

Europe PubMed Central

3 August 2017

1

1 reference

Europe PubMed Central

3 August 2017

71-77

1 reference

Europe PubMed Central

3 August 2017

https://scigraph.springernature.com/pub.10.1007/s00592-010-0220-6

0 references

Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048463

7 July 2018

Exercise for the management of type 2 diabetes: a review of the evidence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048463

7 July 2018

Exercise therapy in type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048463

7 July 2018

Standards of medical care in diabetes--2006

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048463

7 July 2018

Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048463

7 July 2018

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048463

7 July 2018

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048463

7 July 2018

Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048463

7 July 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048463

7 July 2018

The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048463

7 July 2018

Acarbose: its role in the treatment of diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048463

7 July 2018

Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048463

7 July 2018

Pharmacology of alpha-glucosidase inhibition.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048463

7 July 2018

Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048463

7 July 2018

Acarbose : An Update of its Pharmacology and Therapeutic Use in Diabetes Mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048463

7 July 2018

Post-prandial glycaemic reduction by an alpha-glucosidase inhibitor in type 2 diabetic patients with therapeutically attained basal normoglycaemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048463

7 July 2018

Trends in mortality from diabetes mellitus in Taiwan, 1960-1988.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048463

7 July 2018

Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1007%2FS00592-010-0220-6

21 January 2018

Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00592-010-0220-6

21 January 2018

The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00592-010-0220-6

21 January 2018

alpha-Glucosidase inhibitor reduces the progression of carotid intima-media thickness

1 reference

https://api.crossref.org/works/10.1007%2FS00592-010-0220-6

21 January 2018

The U.K. Prospective Diabetes Study. A review.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-010-0220-6

21 January 2018

Cardiovascular risk profile assessment in glucose-intolerant Asian individuals--an evaluation of the World Health Organization two-step strategy: the DECODA Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Asia).

1 reference

https://api.crossref.org/works/10.1007%2FS00592-010-0220-6

21 January 2018

Failure to metformin and insulin secretagogue monotherapy: an observational cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048463

26 October 2018

Mortality and causes of death in a national sample of diabetic patients in Taiwan

1 reference

https://pubmed.ncbi.nlm.nih.gov/20963449

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of N-linked complex oligosaccharide formation by 1-deoxynojirimycin, an inhibitor of processing glucosidases

1 reference

https://pubmed.ncbi.nlm.nih.gov/20963449

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acarbose-induced acute hepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20963449

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acarbose-induced hepatic injury

1 reference

https://pubmed.ncbi.nlm.nih.gov/20963449

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acarbose-associated hepatotoxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/20963449

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?

1 reference

https://pubmed.ncbi.nlm.nih.gov/20963449

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00592-010-0220-6

1 reference

Europe PubMed Central

3 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34623166&oldid=1627770895"